Multi-program deal with revenue potential of $100 million per target SAN DIEGO, Aug. 15, 2026 /PRNewswire/ — Aizen Therapeutics, an AI-native biotechnology company focused on building oral biologics, today announced a multi-program collaboration with a San Diego-based, public biotech to…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
